Navigation Links
1-year results of bronchial thermoplasty in refractory asthma
Date:2/11/2008

Sunnyvale, CA, February 11, 2008 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure under investigation for the treatment of asthma, announced today the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191). The publication reports that despite a transient increase in procedure related adverse events, patients experienced longer term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.

Bronchial thermoplasty is a non-drug treatment for asthma and is currently under clinical investigation. Bronchial thermoplasty is an investigational procedure in which precisely controlled thermal energy is delivered with a tiny catheter to targeted airway walls of patients with asthma. This procedure is intended to reduce muscle in the walls of airways, and thereby decrease the ability of airways to narrow in patients with symptomatic asthma.

The RISA Trial was a randomized trial conducted at a total of eight centers in three countries, and evaluated the safety and efficacy of bronchial thermoplasty in a total of 32 adult subjects, randomized 1:1 between the BT group and Control group with severe persistent asthma who were symptomatic despite taking regular asthma medications.

In this group of patients with severe asthma, an increase in respiratory-related symptoms was expected and observed during the period immediately following the procedure. Most occurred within one day of the procedure and resolved on average within a week. Following the treatment period, respiratory-related symptoms were similar between treatment groups.

Almost 6 months after the procedure, compared to the control group, patients who received bronchial thermoplasty showed clinically and statistically significant improvements in pulmonary function, quality of life and asthma control. In addition, patients in the treatment group used an average of 25 fewer puffs per week of rescue medication than those in the untreated Control group.

All patients then attempted to reduce their inhaled and/or oral corticosteroids (OCS) during a 14 week period. Fifty percent (50%) of bronchial thermoplasty treated patients were able to wean completely off their oral corticosteroids (OCS), compared to 14% of patients who did not receive the treatment. This improvement did not reach statistical significance; however the study was not powered to show statistical significance in medication changes.

One year following treatment, and after the period of medication reduction, patients who received the bronchial thermoplasty procedure continued to show clinically and statistically significant improvements in quality of life and asthma control, and used less rescue medication .

We found that, in this population of severe asthma patients, bronchial thermoplasty was associated with a short-term increase in asthma-related symptoms around the time of treatment but showed a potential for a longer-term improvement in rescue medication use, lung function, asthma control and quality of life, states Ian D. Pavord, MD and principle investigator of the study at the Glenfield General Hospital, University Hospitals of Leicester. These potential long term improvements make us hopeful that bronchial thermoplasty could some day be a viable new treatment option for these severe asthma patients.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
Source:Eurekalert  

Related medicine news :

1. Less than 3 percent of UK 11-year-olds take enough exercise
2. Rural/Metro Announces Results for Fiscal 2008 Second Quarter
3. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
4. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Neurobiological Technologies Reports Second Quarter Financial Results
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
7. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
8. Huntsman to Discuss Fourth Quarter and Full Year 2007 Results on Friday, February 22, 2008
9. Chindex International, Inc. Announces Results for the Quarter and Nine Months Ended December 31, 2007
10. Natural Alternatives International, Inc. Announces Second Quarter Results
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
1-year results of bronchial thermoplasty in refractory asthma
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... and individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT to ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of the ... do not brush their teeth the minimum two times a day that dentists recommend. The ... missing 51 million hours of school and adults missing 164 million hours of work each ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Electrophoresis Market 2017-2021" report to their offering. ... The global capillary electrophoresis market ... The report, Global Capillary Electrophoresis Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/23/2017)... -- CENTRO DE IMAGEM DIAGNOSTICOS S.A. (" Company "), ... 6,404/76 and Instruction 358/02 of the Brazilian Securities and ... market in general that it entered yesterday, as a ... Imagem Ltda. (" CDI "), into an agreement for ... (" Partnership " and " Acquisition "). ...
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
Breaking Medicine Technology: